Cheat sheet

IC&RC ADC Cheat Sheet

Practice this exam

Scientific Principles & Co-Occurring

  • 25% of exam
  • Disease Model Reward Pathway Withdrawal Signs Drug Classes Co-Occurring Conditions

Evidence-Based Screening & Assessment

  • 20% of exam
  • Screening Tools DSM-5-TR Criteria ASAM Dimensions Levels of Care Biopsychosocial History

Treatment, Counseling & Referral

  • 30% of exam
  • Motivational Interviewing Stages of Change MAT Medications Treatment Planning Discharge Planning Recovery Pathways

Professional, Ethical & Legal

  • 25% of exam
  • Boundaries 42 CFR Part 2 Informed Consent Client Rights Supervision

Quick Facts

  • Questions 150 (125 scored, 25 pretest)
  • Time Limit 3 hours
  • Pass Score 500 scaled (200-800)
  • Domains 4 (25/20/30/25%)
  • Retake Wait 90 days minimum
  • Delivery Prometric CBT or remote
  • Blueprint November 2022 edition

Dependence vs Addiction SC

Physical Dependence

  • Withdrawal on stopping
  • Can occur with prescribed meds

Addiction

  • Compulsive use despite harm
  • Loss of control
  • Withdrawal alone isn't addiction

Drug Classes SC

  • CNS Depressants Alcohol, benzos, barbiturates
  • Opioids Pain relief; overdose risk
  • Stimulants Cocaine, methamphetamine
  • Hallucinogens Low dependence potential
  • Cannabis Low acute lethality
  • Inhalants Rapid onset; organ damage

Withdrawal Signs SC

  • Alcohol Withdrawal Tremor; seizures day 1-2
  • Delirium Tremens Life-threatening; later onset
  • Opioid Withdrawal Flu-like; not life-threatening
  • Benzo Withdrawal Seizure risk like alcohol
  • Stimulant Crash Fatigue, low mood, cravings
  • Opioid Overdose Pinpoint pupils, slow breathing

Neurobiology & Risk Factors SC

  • Disease Model Chronic brain condition
  • Reward Pathway VTA to nucleus accumbens
  • Tolerance Need more for effect
  • Physical Dependence Withdrawal on stopping
  • Cross-Tolerance Tolerance carries to similar drugs
  • Top Risk Factors Trauma, family history, early use

ASAM Dimensions 1 to 6 AS

  • D1→D6: Intox-Bio-Psych-Risk-Env-Person
  • D1: Intoxication, withdrawal, meds D2: Biomedical conditions D3: Psychiatric, cognitive conditions D4: Substance use risks D5: Recovery environment D6: Person-centered considerations

CAGE-AID vs ASI AS

CAGE-AID

  • 4-item brief screen
  • 2+ yes flags risk

ASI

  • 7-domain severity interview
  • Guides treatment planning
  • Screen vs comprehensive assessment

Level of Care Picker AS

  • Mild withdrawal, stable support → Level 1 ( Outpatient )
  • Moderate symptoms, some risk → Level 2 ( Intensive outpatient )
  • Needs 24-hour structure → Level 3 ( Residential )
  • Severe withdrawal risk → Level 3.7 ( Medically managed residential )
  • Life-threatening instability → Level 4 ( Medically managed inpatient )
  • Sustained remission, monitoring only → Level 1.0 ( Long-term monitoring )

Screening Tools AS

  • CAGE-AID 4-item; 2+ yes flags
  • ASI 7-domain severity interview
  • SASSI Self-report; detects defensiveness
  • ACE Adverse childhood experiences score
  • AUDIT Alcohol-specific screening tool
  • DAST Drug-specific screening tool

DSM-5-TR SUD Criteria AS

  • Criteria Count 11 total; need 2+
  • Mild 2-3 criteria
  • Moderate 4-5 criteria
  • Severe 6 or more criteria
  • Prescribed Meds Tolerance/withdrawal don't count

ASAM Six Dimensions AS

  • Dimension 1 Intoxication/withdrawal/addiction medications
  • Dimension 2 Biomedical conditions
  • Dimension 3 Psychiatric, cognitive conditions
  • Dimension 4 Substance use-related risks
  • Dimension 5 Recovery environment interactions
  • Dimension 6 Person-centered considerations

ASAM Levels of Care AS

  • Level 1 Outpatient care
  • Level 2 Intensive outpatient
  • Level 3 Residential care
  • Level 4 Medically managed inpatient
  • Level 0.5 Removed in 4th edition
  • Decimals Mark gradation within level

Biopsychosocial History AS

  • Core Areas Medical, family, employment, legal
  • Collateral Sources Family, prior providers
  • Testing Screens Immunoassay; fast, false positives
  • Confirmatory Test GC-MS confirms positive
  • Placement Goal Least restrictive, safe level

OARS Micro-Skills TR

  • Open, Affirm, Reflect, Summarize
  • Open-ended questions Affirmations Reflective listening Summaries

Methadone vs Buprenorphine TR

Methadone

  • Full agonist
  • OTP dispensing only
  • QTc monitoring needed

Buprenorphine

  • Partial agonist
  • Ceiling effect
  • Any qualified prescriber
  • Full agonist vs ceiling effect

MAT Medication Picker TR

  • Active opioid use, OTP access → Methadone ( Full agonist )
  • Office-based opioid treatment → Buprenorphine ( Partial agonist )
  • Opioid-free 7-10 days → Naltrexone ( Antagonist )
  • Alcohol use disorder, adherent → Acamprosate ( Renal dosing )
  • Alcohol use, needs deterrent → Disulfiram ( Aversive reaction )
  • Pregnant with opioid use disorder → Methadone or buprenorphine ( Preferred over withdrawal )

Motivational Interviewing TR

  • OARS Open, Affirm, Reflect, Summarize
  • Change Talk Reinforce statements favoring change
  • Sustain Talk Reflect; don't argue against
  • Spirit Partnership, acceptance, compassion, evocation
  • Ambivalence Normal; not resistance

Stages of Change Order TR

  • Precontemplation -> Contemplation -> Preparation -> Action -> Maintenance
  • Precontemp: not considering Contemplation: weighing pros/cons Preparation: planning to act Action: actively changing Maintenance: sustaining change

Goals vs Objectives TR

Goals

  • Broad desired outcome
  • Long-term direction

Objectives

  • Specific measurable steps
  • Time-limited and trackable
  • Broad vs specific and measurable

Stages of Change TR

  • Precontemplation Not considering change
  • Contemplation Weighing pros and cons
  • Preparation Planning to act soon
  • Action Actively changing behavior
  • Maintenance Sustaining the change

MAT Medication Memory Line TR

  • Methadone full | Bupe partial | Naltrexone blocks
  • Methadone: full agonist, OTP Buprenorphine: partial agonist, ceiling Naltrexone: antagonist, needs opioid-free

Lapse vs Relapse TR

Lapse

  • Single use event
  • Can be learned from

Relapse

  • Return to full use pattern
  • Often follows abstinence violation effect
  • One slip vs full return

MAT Medications TR

  • Methadone Full agonist; OTP-only
  • Buprenorphine Partial agonist; ceiling effect
  • X-Waiver Eliminated 2023 (CAA)
  • Naltrexone Antagonist; needs opioid-free days
  • Vivitrol Wait 7-10 opioid-free days minimum
  • Acamprosate Renal dosing; three times daily
  • Disulfiram Aversive; blocks alcohol metabolism

Domain Weight Order TR

  • 25-20-30-25 percent, I to IV
  • Domain I: 25% Domain II: 20% Domain III: 30% Domain IV: 25%

Treatment Planning & Process TR

  • Goals Broad desired outcome
  • Objectives Specific, measurable, time-limited steps
  • Tuckman Stages Form, storm, norm, perform
  • Relapse Triggers Emotions, conflict, social pressure
  • Abstinence Violation Guilt after single lapse
  • Warm Handoff Direct provider-to-provider connection

Discharge & Recovery Pathways TR

  • Discharge Elements Aftercare, relapse plan, referrals
  • 12-Step Mutual-aid fellowship model
  • SMART Recovery Secular, CBT-based mutual aid
  • Harm Reduction Reduces risk without abstinence
  • Multiple Pathways No single model fits all

Consultation vs Supervision ET

Consultation

  • Informal peer exchange
  • Case-specific question

Supervision

  • Ongoing formal oversight
  • Tracks skill development
  • Informal vs ongoing oversight

42 CFR Part 2 Disclosure Picker ET

  • Routine treatment, payment, operations → Single TPO consent ( 2024 final rule )
  • Bona fide medical emergency → Disclose without consent ( Document the emergency )
  • Law enforcement has subpoena only → Still need consent ( Subpoena alone insufficient )
  • Court orders Subpart E hearing → Disclosure permitted ( Good-cause hearing required )
  • Subcontractor needs client data → QSOA required ( Qualified service agreement )
  • Suspected child abuse, initial report → State law applies ( Initial report exception )

Boundaries & Self-Disclosure ET

  • Dual Relationship Another role with client
  • Self-Disclosure Rule Serves client; stays brief
  • Scope of Practice Set by training, credential
  • Conflict of Interest Disclose; step back

Court Order vs Subpoena ET

Court Order

  • Subpart E hearing required
  • Permits Part 2 disclosure

Subpoena Alone

  • Not sufficient alone
  • No disclosure without order
  • Order compels; subpoena doesn't

42 CFR Part 2 ET

  • 2026 Compliance Required by Feb 16 2026
  • Single TPO Consent Covers treatment, payment, operations
  • SUD Notes Still need separate consent
  • Court Order Subpart E hearing; not subpoena
  • QSOA Qualified service organization agreement
  • Medical Emergency Bona fide exception; no consent

Informed Consent & Rights ET

  • Informed Consent Purpose, risks, benefits, alternatives
  • Voluntary No coercion; can withdraw
  • Client Rights Dignity, refuse care, grievance
  • Grievance Process No retaliation; documented response

Supervision & Documentation ET

  • Supervision Ongoing oversight of casework
  • Consultation Informal case discussion
  • Documentation Standard Objective, timely, specific
  • Record Security Limited access; written policy
  • Cultural Humility Ongoing self-reflection; not checklist

Common Traps

Tolerance ≠ Addiction

  • Tolerance is pharmacological need ≠ Addiction adds compulsive harmful use

Lapse ≠ Relapse

  • Lapse is one slip ≠ Relapse is sustained return

Consultation ≠ Supervision

  • Consultation is informal peer input ≠ Supervision is ongoing formal oversight

Subpoena ≠ Court Order

  • Subpoena alone is insufficient ≠ Court order needs Subpart E hearing

CAGE-AID ≠ Diagnosis

  • CAGE-AID only screens risk ≠ DSM-5-TR criteria give diagnosis

Readiness ≠ Standalone Dimension

  • 4th edition assesses readiness everywhere ≠ Dimension 4 now substance use risks

Methadone ≠ Buprenorphine

  • Methadone is full agonist ≠ Buprenorphine is partial with ceiling

Last Minute

  • 1. Weights: 25-20-30-25 percent
  • 2. 150 questions; 125 scored only
  • 3. Pass is 500 scaled score
  • 4. 90-day minimum wait to retake
  • 5. 4 failed attempts trigger remediation
  • 6. ASAM 4th edition: six dimensions
  • 7. Part 2 compliance due Feb 2026
  • 8. Single consent now covers TPO
  • 9. Naltrexone needs 7-10 opioid-free days
  • 10. Buprenorphine needs no federal X-waiver
  • 11. OARS = core MI skills
  • 12. DSM-5-TR severe means 6+ criteria

IC&RC Alcohol & Drug Counselor (ADC) Examination

  • Practice Questions 165 questions Study Guide 56 topics Cheat Sheet 93 facts Flashcards 50 cards Free CE Podcast